Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs
(CHANCE Trial)

Recruiting in Palo Alto (17 mi)

+95 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: European Foundation for Study of Chronic Liver Failure

No Placebo Group

Trial Summary

What is the purpose of this trial?

Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.

Research Team

Eligibility Criteria

Inclusion Criteria

1. Male or female subject ≥18 years of age.

2. Subjects with diagnosis of liver cirrhosis (based on clinical, laboratory, endoscopic, and ultrasonographic features or on histology).

Group 1: patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list.

See 3 more

Treatment Details

Interventions

Liver Transplantation (N/A)

Participant Groups

3Treatment groups

Experimental Treatment

Group I: Group 3Experimental Treatment1 Intervention

patients having ACLF-2 or 3, are assessed for inclusion in the waiting list, but are finally not listed for liver transplantation (n=500)

Group II: Group 2Experimental Treatment1 Intervention

patients listed for liver transplantation with decompensated cirrhosis without ACLF-2 or 3 and poor liver function (MELD \> 20) at the time of listing (n=500)

Group III: Group 1Experimental Treatment1 Intervention

patients listed for liver transplantation with ACLF-2 or 3 at the time of listing or developing ACLF 2-3 while on the waiting list (n=2,000)